SUMMARY (284.9 (217.8-362.2) min vs 226.8 (201.2-250) 
Alfentanil undergoes extensive metabolism in the liver, by microsomal oxidative N-dealkylation. It might therefore be expected that alterations in drug disposition would be seen in the presence of liver disease.
In a previous study, Ferrier and colleagues [2] demonstrated a significant reduction in the plasma protein binding and plasma clearance of alfentanil in patients with alcoholic cirrhosis. The apparent volume of distribution at steady state (F") was unaltered. Plasma albumin concentrations were decreased, but there was no difference in the plasma concentrations of o^-acid glycoprotein, an acute phase protein that is an important binding site for alfentanil [3] .
Blaschke [4] suggested that, as different types of liver disease vary in their relative emphases on changes in liver cell function, liver blood mass and liver blood flow, so pathological differences may present as a spectrum of altered pharmacokinetics for a given drug. For example, a drug with clearance in the liver, being mainly flow-dependent, is affected more than a capacity-limited drug under circumstances in which liver blood flow is more compromised than hepatocellular function (and vice versa) .
Little work has been presented yet which investigates this hypothesis. Often the term "cirrhosis" has been used as a general description for patients with liver disease-irrespective of the aetiology.
In the present study, we have examined the disposition and protein binding of the opioid alfentanil used as part of a balanced anaesthetic technique in patients with hepatic dysfunction of different aetiologies: alcoholic liver disease (w = 6) or nonalcoholic cirrhosis (n=ll), and compared these with data from six healthy, anaesthetized patients with no clinical or laboratory evidence of liver disease.
PATIENTS AND METHODS
All patients were unpremedicated, and gave their informed consent to the study, which was approved by the local Hospital Ethics Committee. Seventeen patients with liver dysfunction of alcoholic (n = 6) or non-alcoholic aetiology were undergoing endoscopic ligation of oesophageal varices; six control subjects were undergoing upper endoscopic investigations or body surface surgery of similar duration. The aetiologies of the non-alcohol-related liver dysfunction group were micro/macronodular cirrhosis (n = 3), cirrhosis secondary to portal vein thrombosis (n = 3), cirrhosis secondary to chronic active hepatitis (n = 2), cryptogenic cirrhosis (n = 2) and primary biliary cirrhosis (n = 1). A diagnosis of alcoholic related dysfunction was made only on the basis of a positive history of alcohol abuse, and positive histological changes (enlargement and disorganization of mitochondrial cristae, decreased number of intramitochondrial inclusion bodies, presence of hyaline Mallory Bodies, and increased number of perioxisomes).
Anaesthesia was induced with etomidate 12-20 mg, the trachea intubated after neuromuscular block with vecuronium 0.1 mg kg" 1 , and anaesthesia was maintained with 60-70% nitrous oxide in oxygen supplemented by isoflurane (< 1.0%). When stable anaesthesia had been attained, analgesia was provided by a bolus dose of alfentanil 500 ug given i.v. over 20 s into a flowing peripheral infusion.
Blood sampling and alfentanil analyses
Peripheral blood was sampled from the contralateral arm before injection of alfentanil, and then at regular intervals from 2 min to 24 h: at 2, 4, 6, 8, 10, 15,20,25, 30,45 and 60 min, every 30 min to 6 h and then at 8, 20 and 24 h. Blood was separated by centrifugation, and the plasma stored at -20 °C until assay for alfentanil by a radioimmunoassay [5] . The sensitivity of the assay was 2 pg ml" 1 , and the intra-assay coefficients < 10% over the concentration range measured. 3 H-Alfentanil and the rabbit anti-alfentanil antibody were obtained from Janssen Pharmaceutica BV, Beerse, Belgium. With this antibody there is no cross-reactivity to any of the known metabolites of alfentanil [6] . Each sample was assayed in duplicate.
Drug binding to plasma proteins was measured at 37 °C and pH 7.4 using equilibrium dialysis against phosphate buffer 1 mol litre" 1 [7] .
Laboratory investigations
All patients had the following biochemical indices measured: total plasma protein, serum albumin, serum bilirubin and aspartate aminotransferase concentrations, and prothrombin time (SMAC parallel analyser). otj-Acid glycoprotein (AAG) was measured by radioimmunodiffusion.
Kinetic analyses
Plasma concentration-time data were analysed by non-compartmental methods. The area under the concentration-time curve (AJJCQ^ and its first moment were calculated using the linear trapezoidal rule. The area under the curve between the last data point (C t ) and infinity was calculated as CJk, where k = elimination rate constant determined by nonlinear regression analysis. Mean residence time (MRT), clearance (C/ P ) and apparent volume of distribution at steady state (F**) were calculated according to Benet and Galeazzi [8] . Free drug kinetic parameters were obtained by dividing C/ P and V s by the free drug fraction to give C/ P u and
Statistical analyses
Overall differences between groups were determined using ANOVA, and between pairs of groups using the Mann-Whitney U test. Data are shown in the tables as mean (SD) and range. Significance is assumed at P < 0.05.
RESULTS
Anaesthesia and the postoperative period were uneventful in all subjects. There were no significant differences between the three patient groups in age and weight, but there was a greater number of female subjects in the group with non-alcohol related hepatic dysfunction. Baseline biochemical data are shown in table I.
Examining total drug kinetics, there were significant differences in clearance between the three groups ( fig. 1 ). This was reduced in the non-alcoholic group compared with controls (P < 0.05). Inspection of the data suggested a bimodal distribution of clearance values in the former group, with smaller estimates in patients with cirrhosis secondary to portal venous thrombosis (n = 3), micro/macronodular cirrhosis secondary to post-transfusion hepatitis B (n = 1) and autoimmune aetiology (« = 2). MRT was prolonged in the alcoholic group compared with controls (P < 0.05). There was a signifi- cant difference between the two liver dysfunction groups in V" (P < 0.05) (table II) . Alfentanil binding to plasma proteins was reduced also in the alcoholic group compared with controls (P < 0.05). As a result, free drug clearance was reduced significantly in the non-alcoholic group compared with control subjects (P < 0.05); there were also decreases in the V**u in both liver dysfunction groups (P < 0.05 non-alcoholic group vs controls; P < 0.05 alcoholic group vs controls). There were no differences in the serum albumin concentration between the three groups; however, AAG concentration was significantly reduced in the alcoholic group (P < 0.05 vs controls).
There was no significant correlation within the liver dysfunction patients between total or free drug clearance and any of the biochemical variables.
DISCUSSION
The liver is one of the main sites of drug metabolism. In the presence of liver dysfunction, alterations in drug clearance may be expected. However, there are several different and separate factors that interplay with each other: liver flood flow, liver microsomal enzyme activity and protein and tissue binding of drugs [9] . Thus the increased free fraction in liver dysfunction may counterbalance the decrease in mixed function oxygenase activity. Our present data indicate that alterations in drug disposition and elimination in patients with hepatic disease may be dependent (at least in part) on the aetiology of the liver dysfunction.
In cirrhosis, there is usually marked fibrosis and nodular regeneration, resulting in circulatory changes of importance to the handling of drugs (e.g. porto-systemic intra-and extrahepatic shunting; increased plasma volume; increased cardiac output; peripheral pooling of blood; hypoalbuminaemia). Acute viral hepatitis and alcoholic liver disease have predominant effects on the pericentral regions of the hepatic lobules and are more likely, therefore, to be associated with impairment of oxidative metabolism. In contrast, chronic active hepatitis and primary biliary cirrhosis affect mainly the periportal regions, and have little effect on drug metabolism [10] . This is borne out by clearance values similar to the control group in patients with chronic active hepatitis and primary biliary cirrhosis, and reduced in patients with alcohol-related liver disease and portal venous thrombosis.
The enzymes involved in glucuronide conjugation are located throughout the liver parenchyma, with the greatest concentrations in the periportal region. Preservation of glucuronidation in chronic liver disease has been attributed to three findings: the large reserve in glucuronide transferase enzyme activity; the more protected locale of the enzymes; and extrahepatic metabolism [11] .
The clearance and apparent volume of distribution estimates for the control patients are comparable to those reported in other anaesthetized patients undergoing artificial ventilation of the lungs, in whom blood sampling has been continued for > 10 h after dosing [2, 12] . Such sampling regimens identify a longer estimate for the elimination half-life and smaller clearance values than are reported in studies using shorter sampling periods.
This study and that by Ferrier and colleagues [2] have shown that liver dysfunction causes greater alterations in alfentanil disposition than has been reported previously for its congeners, fentanyl and sufentanil [13, 14] . Both the latter studies reported no effect of liver disease (mainly alcohol-related cirrhosis) on drug elimination half-life and plasma clearance. The reduced binding of alfentanil in patients with alcoholic liver disease is in agreement with the data of Ferrier's group [2] and is primarily the result of the change in plasma AAG concentrations [3] . In the latter regard, our data are at variance with those of Ferrier and co-workers, who found differences in AAG concentrations. This suggests that in our alcoholic group the degree of liver dysfunction was greater, with impaired biosynthetic activity of AAG. Greater free drug concentrations coupled with a decrease in systemic drug clearance in patients with hepatic dysfunction may result in enhanced or prolonged effects of the opioid when administered in large bolus doses, or by multiple increments or continuous infusion.
Cirrhosis influences the clearance of many i.v. drugs administered during anaesthesia. However, the effect is not uniform, thus the clearance of morphine has been reported as being both unaltered and reduced [15, 16] , while that of sufentanil is apparently unaffected [14] . Yet both drugs exhibited flow-dependent clearances. A study by Colli and colleagues has compared the effects of cirrhosis on the disposition of the flow-limited drug lignocaine and the capacity-limited drug theophylline in the same individuals [17] . There was a high correlation of the degrees of impairment of both theophylline and lignocaine clearances, but only the decrease in lignocaine clearance correlated closely with the severity of the liver disease (as classified by the Child's Classification). This is further evidence for the non-uniformity of the effects of disease processes on drug handling in the body.
In summary, this study has compared the influence of different types of liver dysfunction on alfentanil disposition. Reduction in clearance appeared to be dependent only partly on the aetiology of the disease process. Our data (and those of Ferrier and colleagues [2] ) indicate wide interindividual variability in alfentanil kinetics. The decrease in clearance in patients with liver disease is in contrast with the unaltered disposition of both fentanyl and sufentanil. Thus the latter opioids may provide a more predictable effect when used as part of a balanced anaesthetic technique in patients with hepatic impairment.
